The w-oxidation of fatty acids results in the formation of medium-and long-chain dicarboxylates. By this accessory metabolic pathway monocarboxylic acids are first converted into w-hydroxymonocarboxylic acids, a reaction catalysed by the microsomal mixed-oxidase function system (Pettersen, 1972) . These intermediates are subsequently converted into w-oxomonocarboxylic acids and dicarboxylic acids by the action of cytosolic alcohol-and aldehyde-dehydrogenases (Mitz & Heinrikson, 196 1 ) . Medium-chain dicarboxylic acids can be formed from long-chain dicarboxylic acids and be excreted in urine. This organic aciduria is increased in a variety of conditions with excessive fatty acid degradation such as ketosis and diabetes mellitus or secondarily to defective mitochondrial fatty acid oxidation, including inherited metabolic defects, hypoglycin intoxication and riboflavin deficiency, as well as in subjects receiving medium-chain triacylglycerols. Dicarboxylic acids can be activated to their CoA esters by a rat liver microsomal synthetase (Vamecq et ul., 1985) . In clofibrate-treated rats, esters of long-and medium-chain dicarboxylic acids can be /3-oxidized by both liver mitochondrial and peroxisomal fractions (Kolvraa & Grcgersen, 1986) , whereas in control animals this catabolism is mainly peroxisomal (Vamecq, 1987) . Our studies were thus mainly dedicated to the catabolism of dicarboxylic acids in control, riboflavin-deficient and clofibrate-treated rats in vivo. The shortening of dicarboxylates by isolated mitochondria from the livers of control rats was also investigated.
Thc rate of oxidation of dodecanedioic acid was studied in the three groups of animals by the following procedure. Anaesthetized rats were cannulated to give direct access to blood, and urine was continuously collected from the bladder. Dodecanedioic acid was infused in the form of its Na salt in doses of 11, 22 and 44 pmol per 100 g body weight during a 30 min period. Urine was collected over 30 min periods from 1 h before to 3 h after infusion. Organic acids were extracted, and trimethylsilylated derivatives were separated and detected by gas chromatography using an Intersmat IGC-12 1 DC gas chromatograph (Suresnes, France) coupled to an Intersmat ICR-1B integrator and equipped with a 50 m capillary column (0.32 mm in diameter, Chrompack CP Sil 5 fused silica) as previously described (Draye et ul., 1987) .
In control and riboflavin-deficient rats, dodecanedioic acid (22 pmo1/100 g body weight) was rapidly transformed into adipic, suberic and sebacic acids, which appeared in urine (Fig. I) . Excretion of succinic acid remained low and was not modified by the infusion. In control animals, this process lasted less than 2 h, and urinary dicarboxylic acids amounted to 28.6 f 1.0% (mean f S.E.M; 11 = 4) of the dose administered. Over 60"% of this excretion occurred within 30 min after the infusion period. In riboflavin-deficient rats, the process was slower and not complete 3 h after infusion; dicarboxylic acids in urine amounted to 75.6 k 15.5% ( n = 3 ) of the infused dose. In clofibrate-treated rats, only 4.4 f 1.2%
( n = 3 ) of dodecanedioic acid was recovered as shorter dicarboxylic acids in urine.
The maximal apparent velocity of dicarboxylate oxidation as calculated from the initial rate of appearance of mediumchain dicarboxylic acids in urine is similar in control and riboflavin-deficient animals. This rate of P-oxidation corresponds to the formation of 10.0 pmol of acetyl-CoA/30 min per 100 g body weight in controls, and 14.8 pmol/30 min per 100 g body weight in riboflavin-deficient rodents. The livers of the latter animals were 1.4 times larger than those of controls, when expressed as a percentage of body weight. In control rats the experiment was repeated with 11 and 44 pmol of dodecanedioic acid and, surprisingly, the same proportions of shorter dicarboxylic acids were recovered in urine (22.1 and 24.9%, respectively compared to 28.6%). Over 70%) of the infused dodecanedioic acid was never recovered in urine, irrespective of dose, the rate of which is presently unknown.
Using the ferricyanidc method of Osmundsen &L Bremer (1977) we showed in preliminary experiments that there was no detectable oxidation by intact mitochondria from control rat liver of sebacyl-CoA in the presence of L-carnitine. The same acyl-CoA was a convenient substrate for the peroxi- clofihrute-rreuted ruts Dodecanedioic acid (DC 12) was infused intravenously (22 pmol/ 100 g body weight) at a concentration of 5 mg/ml in 5% (w/v) bovine serum albumin in 0.15 M-NaCI during the period 0, as indicated by hatched areas. Urinary adipic, suberic and sebacic acids were quantified by gas chromatography.
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BIOCHEMICAL SOCIETY TRANSACTIONS soma1 oxidase ( H 2 0 , production) . Nevertheless, mitochondrial oxidation of sebacyl-carnitine could be recorded. This activity was 10-20% of that measured in the same mitochondrial preparation with palmitoyl-CoA ( + L-carnitine) or decanoyl-carnitine. Further, there was no indication of interference by sebacyl-CoA with carnitine palmitoyltransferase.
In conclusion, intravenously infused dodecanedioic acid is readily catabolized in control rats in which less than 30% of the infused dose is recovered in urine as shorter dicarboxylates. Further experiments with radiolabelled dicarboxylates are necessary to determine the fate of the remaining 70%; the possibility exists that they are completely oxidized in mitochondria. Indeed, we showed by experiments in vitro that mitochondria are able to oxidize dicarboxyl-carnitine esters, although the mechanism of formation of these esters was not elucidated. Dicarboxyl-carnitine esters do not appear to be formed by mitochondrial carnitine palmitoyltransferase. Riboflavin deficiency, which induces a profound impairment of the activities of mitochondrial, but not of peroxisomal, flavoproteins and thus induces by itself a dicarboxylic aciduria, considerably increases the proportion of dicarboxylates recovered in urine from the infused dodecanedioic acid. The administration of clofibrate, a drug which, among other effects, stimulates both mitochondrial and peroxisomal poxidation in rats, strongly decreases the excretion of dicarboxylates in urine.
It itrodir ction
During the last decade, several new inborn errors of mitochondrial and peroxisomal fatty acid oxidation have been described. These inborn errors of metabolism are likely to be much more common than has been recognized until now, and they may present in a variety of different ways. This review will be confined to the inborn errors of mitochondrial P-oxidation, and it will report the recent progress that has been made in the study of these disorders. Progress in understanding disorders of peroxisomal /?-oxidation has been described elsewhere (Fahimi & Sies, 1987) .
Investigutions of defects ofjutty ucid oxidution
The most important initial investigations to be performed in patients with suspected defects of fatty acid oxidation are the determination of the circulating blood concentrations of intermediary metabolites and of urinary organic acids. Hypoglycaemia, when associated with low blood ketone body concentrations and normal or high non-esterified fatty acid concentrations, strongly suggests that a defect of fatty acid oxidation is likely to be present. A defect of mitochondrial P-oxidation is often associated with the excretion of abnormal metabolites in the urine, and these metabolites can be detected by analysing the urine by gas chromatography, gas chromatography-mass spectrometry and high performance liquid chromatography. Thus, in the presence of a defect of mitochondrial fatty acid oxidation, long-chain fatty acids may be directed to w-oxidation which is followed by A. AYNSLEY-GREEN?
Abbreviations used: CPT, carnitine palmitoyltransferase; ETF, electron transfer flavoprotein; ETF-QO, electron transfer flavoprotein:ubiquinone oxidoreductase.
peroxisomal /%oxidation to form dicarboxylic acids that arc subsequently excreted (Van Hoof et ul.. 1988) . Moreover, the accumulation of acyl-CoA esters in the mitochondrial matrix is associated with the increased urinary excretion of acylcarnitines and glycine conjugates owing to the action o f carnitine acyltransferases and glycine-N-acylasc, respectively. These metabolites can be of substantial diagnostic value, thus for example, the presence of medium-chain dicarboxylic acids, suberylglycine and octanoylcarnitine. are very suggestive of medium-chain acyl-CoA dehydrogcnase deficiency (Bhuiyan et ul., 1987) . However, the urinary excretion of abnormal metabolites can be extremely variable. and some patients under non-stressed conditions may not excrete any abnormal metabolites. It is imperative, therefore, to obtain appropriate blood and urine samples when the patient has a spontaneous episode of illness. If this is not possible, then samples should be collected during metabolic stress induced by carefully controlled fasting in hospital. The starvation test is potentially very dangerous, particularly in childrep, and it should only be performed by individuals experienced in metabolic investigations. The next step in the investigation is to measure the flux through fatty acid oxidation either radiochemically or spectrophotometrically using cultured fibroblasts or tissues from the patient. If these investigations are abnormal, direct assay of the individual enzymes of B-oxidation is required.
Etizyme defects
There are 15 enzymes involved in the P-oxidation of saturated fatty acids and defects of seven of these have been described to date (see below). N o defects have yet been reported in patients of carnitine/acylcarnitine translocase. the enoyl-CoA hydratases, the hydroxyacyl-CoA dehydrogenases, the long-chain 3-oxoacyl-CoA thiolase or of the auxiliary enzymes required for the oxidation of polyunsaturated fatty acids. Carnitine deficiency has been discussed recently (Turnbull & Sherratt, 1985) . The syndromes in which enzyme deficiencies have been found will now be discussed.
